JP2014148552A5 - - Google Patents

Download PDF

Info

Publication number
JP2014148552A5
JP2014148552A5 JP2014108079A JP2014108079A JP2014148552A5 JP 2014148552 A5 JP2014148552 A5 JP 2014148552A5 JP 2014108079 A JP2014108079 A JP 2014108079A JP 2014108079 A JP2014108079 A JP 2014108079A JP 2014148552 A5 JP2014148552 A5 JP 2014148552A5
Authority
JP
Japan
Prior art keywords
compound
dose
composition
medicament
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014108079A
Other languages
English (en)
Japanese (ja)
Other versions
JP5976036B2 (ja
JP2014148552A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014148552A publication Critical patent/JP2014148552A/ja
Publication of JP2014148552A5 publication Critical patent/JP2014148552A5/ja
Application granted granted Critical
Publication of JP5976036B2 publication Critical patent/JP5976036B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014108079A 2008-08-20 2014-05-26 有機ヒ素化合物および癌を処置するための方法 Active JP5976036B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18951108P 2008-08-20 2008-08-20
US61/189,511 2008-08-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011523888A Division JP5933896B2 (ja) 2008-08-20 2009-08-14 有機ヒ素化合物および癌を処置するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015068284A Division JP2015120755A (ja) 2008-08-20 2015-03-30 有機ヒ素化合物および癌を処置するための方法

Publications (3)

Publication Number Publication Date
JP2014148552A JP2014148552A (ja) 2014-08-21
JP2014148552A5 true JP2014148552A5 (US07981874-20110719-C00313.png) 2015-05-14
JP5976036B2 JP5976036B2 (ja) 2016-08-23

Family

ID=41707414

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011523888A Active JP5933896B2 (ja) 2008-08-20 2009-08-14 有機ヒ素化合物および癌を処置するための方法
JP2014108079A Active JP5976036B2 (ja) 2008-08-20 2014-05-26 有機ヒ素化合物および癌を処置するための方法
JP2015068284A Withdrawn JP2015120755A (ja) 2008-08-20 2015-03-30 有機ヒ素化合物および癌を処置するための方法
JP2016191062A Active JP6315841B2 (ja) 2008-08-20 2016-09-29 有機ヒ素化合物および癌を処置するための方法
JP2017242759A Pending JP2018039853A (ja) 2008-08-20 2017-12-19 有機ヒ素化合物および癌を処置するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011523888A Active JP5933896B2 (ja) 2008-08-20 2009-08-14 有機ヒ素化合物および癌を処置するための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015068284A Withdrawn JP2015120755A (ja) 2008-08-20 2015-03-30 有機ヒ素化合物および癌を処置するための方法
JP2016191062A Active JP6315841B2 (ja) 2008-08-20 2016-09-29 有機ヒ素化合物および癌を処置するための方法
JP2017242759A Pending JP2018039853A (ja) 2008-08-20 2017-12-19 有機ヒ素化合物および癌を処置するための方法

Country Status (19)

Country Link
US (4) US20110269697A1 (US07981874-20110719-C00313.png)
EP (2) EP2321012B1 (US07981874-20110719-C00313.png)
JP (5) JP5933896B2 (US07981874-20110719-C00313.png)
KR (3) KR20170103023A (US07981874-20110719-C00313.png)
CN (2) CN104800828A (US07981874-20110719-C00313.png)
AU (1) AU2009282972A1 (US07981874-20110719-C00313.png)
BR (1) BRPI0918407A2 (US07981874-20110719-C00313.png)
CA (1) CA2734650A1 (US07981874-20110719-C00313.png)
DK (2) DK3388111T3 (US07981874-20110719-C00313.png)
ES (2) ES2703740T3 (US07981874-20110719-C00313.png)
HK (2) HK1254607A1 (US07981874-20110719-C00313.png)
IL (1) IL211153A0 (US07981874-20110719-C00313.png)
MX (1) MX2011001800A (US07981874-20110719-C00313.png)
NZ (1) NZ591181A (US07981874-20110719-C00313.png)
PT (2) PT2321012T (US07981874-20110719-C00313.png)
RU (1) RU2534606C2 (US07981874-20110719-C00313.png)
SG (3) SG10201810449XA (US07981874-20110719-C00313.png)
WO (1) WO2010021928A1 (US07981874-20110719-C00313.png)
ZA (1) ZA201101216B (US07981874-20110719-C00313.png)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899486A (zh) * 2013-12-05 2016-08-24 日本苏爱康制药有限公司 用于治疗癌症的化合物和方法
CN104151397A (zh) * 2014-07-03 2014-11-19 北京大学 一类新型三硫杂二环有机砷化物及其合成方法和在抗肿瘤领域里的应用
JP6413969B2 (ja) * 2015-07-29 2018-10-31 住友金属鉱山株式会社 日射遮蔽体形成用分散液および当該分散液を用いた日射遮蔽体
WO2019220961A1 (ja) * 2018-05-18 2019-11-21 ソレイジア・ファーマ株式会社 ダリナパルシンのアルカリ金属塩及び/又は無機酸付加塩の結晶型及びその製剤
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US234972A (en) 1880-11-30 William ennis
US761900A (en) 1904-03-05 1904-06-07 Newton Jefferson Norman Flux compound.
US2349729A (en) 1940-08-24 1944-05-23 Parke Davis & Co Therapeutic arsenic preparation
US6875451B2 (en) 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
PL343868A1 (en) 1997-11-10 2001-09-10 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
DE60118172T2 (de) 2000-04-26 2007-03-08 Oregon Health Sciences University, Portland Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält
DE10132625A1 (de) 2001-07-05 2003-01-23 Oce Printing Systems Gmbh Verfahren, Computerprogrammprodukt und Gerätesystem zum visuellen Überprüfen von Bilddaten
JP4571408B2 (ja) 2002-01-07 2010-10-27 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
TWI411431B (zh) 2004-07-16 2013-10-11 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
EP2394702B1 (en) * 2005-07-29 2014-12-31 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
WO2007082104A2 (en) * 2006-01-13 2007-07-19 The Texas A & M University System Compounds and methods for the treatment of cancer
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
CA2694987A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
US20090053168A1 (en) * 2007-07-17 2009-02-26 Richard Rickles Treatments of b-cell proliferative disorders
KR20100100835A (ko) * 2007-11-02 2010-09-15 지오팜 온콜로지 인코포레이티드 유기 비소제와의 병용 요법
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Similar Documents

Publication Publication Date Title
JP2020097577A5 (US07981874-20110719-C00313.png)
JP2016515561A5 (US07981874-20110719-C00313.png)
JP2014148552A5 (US07981874-20110719-C00313.png)
JP2016508134A5 (US07981874-20110719-C00313.png)
JP2017186358A5 (US07981874-20110719-C00313.png)
JP2016528301A5 (US07981874-20110719-C00313.png)
JP2016518337A5 (US07981874-20110719-C00313.png)
JP2015078230A5 (US07981874-20110719-C00313.png)
JP2016536286A5 (US07981874-20110719-C00313.png)
JP2016530259A5 (US07981874-20110719-C00313.png)
JP2015110588A5 (US07981874-20110719-C00313.png)
JP2012255026A5 (US07981874-20110719-C00313.png)
JP2016510326A5 (US07981874-20110719-C00313.png)
JP2013519675A5 (US07981874-20110719-C00313.png)
JP2012193216A5 (US07981874-20110719-C00313.png)
JP2013518107A5 (US07981874-20110719-C00313.png)
JP2016515628A5 (US07981874-20110719-C00313.png)
JP2019516739A5 (US07981874-20110719-C00313.png)
JP2015516419A5 (US07981874-20110719-C00313.png)
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2015516427A5 (US07981874-20110719-C00313.png)
JP2016539157A5 (US07981874-20110719-C00313.png)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
JP2016537338A5 (US07981874-20110719-C00313.png)